STOCK TITAN

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Biotricity (OTCQB:BTCY) has scheduled its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call for November 15, 2024, at 4:30 PM ET. The company announces its best financial performance to date, highlighting improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA. The call will feature CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou, followed by an investor Q&A session. A replay will be available for approximately 3 hours after the live call through November 29, 2024.

Biotricity (OTCQB:BTCY) ha programmato la sua chiamata per i risultati finanziari del quarto trimestre dell'anno fiscale 2024 e aggiornamenti aziendali per il 15 novembre 2024, alle 16:30 ET. L'azienda annuncia la sua migliore performance finanziaria fino ad oggi, evidenziando i miglioramenti nei margini, nell'efficienza operativa e un passaggio a un EBITDA rettificato positivo. La chiamata vedrà la partecipazione del CEO Dr. Waqaas Al-Siddiq e del CFO John Ayanoglou, seguita da una sessione di domande e risposte con gli investitori. Una registrazione sarà disponibile per circa 3 ore dopo la chiamata dal vivo fino al 29 novembre 2024.

Biotricity (OTCQB:BTCY) ha programado su llamada de resultados financieros del cuarto trimestre del año fiscal 2024 y actualización empresarial para el 15 de noviembre de 2024, a las 4:30 PM ET. La compañía anuncia su mejor desempeño financiero hasta la fecha, destacando mejoras en márgenes, eficiencia operativa y un cambio hacia un EBITDA ajustado positivo. La llamada contará con la participación del CEO Dr. Waqaas Al-Siddiq y el CFO John Ayanoglou, seguida de una sesión de preguntas y respuestas con los inversores. Una repetición estará disponible durante aproximadamente 3 horas después de la llamada en vivo hasta el 29 de noviembre de 2024.

Biotricity (OTCQB:BTCY)는 2024 회계 연도 4분기 재무 결과 및 비즈니스 업데이트 전화를 2024년 11월 15일 오후 4시 30분 ET로 예정하였습니다. 회사는 지금까지의 최고의 재무 성과를 발표하며, 마진 개선, 운영 효율성 향상, 긍정적인 조정 EBITDA로의 전환을 강조합니다. 이 통화에는 CEO 드. 와카스 알시디크와 CFO 존 아야노글루가 참석하며, 이후 투자자 Q&A 세션이 진행됩니다. 라이브 통화 후 약 3시간 동안 2024년 11월 29일까지 다시 들을 수 있습니다.

Biotricity (OTCQB:BTCY) a prévu son appel concernant les résultats financiers du quatrième trimestre de l'exercice fiscal 2024 et la mise à jour de l'entreprise pour le 15 novembre 2024 à 16h30 ET. La société annonce sa meilleure performance financière à ce jour, mettant en avant des améliorations des marges, de l'efficacité opérationnelle et un passage à un EBITDA ajusté positif. L'appel mettra en vedette le PDG Dr. Waqaas Al-Siddiq et le CFO John Ayanoglou, suivi d'une session de questions-réponses avec les investisseurs. Un enregistrement sera disponible pendant environ 3 heures après l'appel en direct jusqu'au 29 novembre 2024.

Biotricity (OTCQB:BTCY) hat seinen Termin für die telefonische Bekanntgabe der finanziellen Ergebnisse des vierten Quartals des Geschäftsjahres 2024 sowie des Geschäftupdates auf den 15. November 2024 um 16:30 Uhr ET angesetzt. Das Unternehmen gibt seine bislang beste finanzielle Leistung bekannt und hebt Verbesserungen bei den Margen, der betrieblichen Effizienz und den Wechsel zu einem positiven bereinigten EBITDA hervor. An dem Anruf werden CEO Dr. Waqaas Al-Siddiq und CFO John Ayanoglou teilnehmen, gefolgt von einer Q&A-Session für Investoren. Eine Wiederholung wird etwa 3 Stunden nach dem Live-Anruf bis zum 29. November 2024 verfügbar sein.

Positive
  • Company reports best financial performance to date
  • Achievement of positive adjusted EBITDA
  • Improved margins and operational efficiency
Negative
  • None.

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.

Event: Biotricity Second Quarter FY 2025 Financial Results and Business Update Call
Date: Friday, November 15, 2024
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 877-269-7751
International: 1-201-389-0908
Webcast URLhttps://viavid.webcasts.com/starthere.jsp?ei=1697705&tp_key=6ae5e1a902

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.

Toll Free Replay Number: 844-512-2921
International: 1-412-317-6671
Replay Access ID: 13750135
Expiration: November 29, 2024 at 11:59 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com


FAQ

When is Biotricity (BTCY) hosting its Q4 FY2024 earnings call?

Biotricity (BTCY) will host its Q4 FY2024 earnings call on November 15, 2024, at 4:30 PM ET (1:30 PM PT).

What financial improvements has Biotricity (BTCY) announced for Q4 FY2024?

Biotricity has announced its best financial performance to date, including improvements in margins, operational efficiency, and a shift to positive adjusted EBITDA.

How long will the replay of Biotricity's (BTCY) Q4 earnings call be available?

The earnings call replay will be available until November 29, 2024, at 11:59 PM ET.

BIOTRICITY INC

OTC:BTCY

BTCY Rankings

BTCY Latest News

BTCY Stock Data

14.29M
22.02M
44.43%
3.85%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY